salvage therapy – Medxy AI

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY 02/20/2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.

$Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia$

Hematology-Oncology news

Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia

By MedXY 01/13/2026

A multicentre phase 2 trial demonstrates that the combination of venetoclax and azacitidine achieves a 76% overall response rate in relapsed or refractory T-ALL, offering a manageable and effective alternative for a patient population with traditionally poor prognoses.

Infectious Diseases news

Olorofim Offers a New Salvage Option for Drug‑Resistant Invasive Fungal Disease — Phase 2b Results

By MedXY 11/24/2025

Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studies.